Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) | PAR-19-348 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer… More | ||
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-21-006 | NCI | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the… More | ||
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | PAR-20-131 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational… More | ||
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional) | PAR-19-251 | NCI | The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous… More | ||
| Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional) | RFA-CA-21-019 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U24 resource-related… More | ||
| Revision Applications for Mechanisms of Drug Resistance (U01 Clinical Trials Not Allowed) | RFA-CA-19-050 | NCI | This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support… More |
||
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) | RFA-CA-21-012 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P50 specialized centers.… More | ||
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-21-033 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-… More | ||
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional) | PA-19-112 | NCI | This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-… More | ||
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) | PAR-19-350 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer… More |